Insider Purchases: Inside the Buy
Tag: CEO insider buying
Magnera: Insiders Keep Buying… Should You?
Magnera’s boardroom is buying diapers—literally. With insiders piling in and free cash flow returning, this specialty materials firm might be worth more than just its wipes. But don’t forget the debt and diaper jokes.
Can Lyft Ever Lift Off or Will It Forever Uber-Underwhelm?
CEO David Risher has been scooping up Lyft shares like surge-priced burritos—and with record rides, rising cash flow, and a $750M buyback plan, the bullish case is stronger than ever. But can LYFT finally fly—or is Uber still driving the narrative?
Xerox Holdings: This Company Still Exists—To Be or Not To Be... In Your Portfolio?
Xerox might feel like yesterday’s news, but insiders and institutions clearly disagree. With executives loading up on shares and a reinvention strategy underway, this classic name could be more than a relic—it might just be your next contrarian play. 📠💥
Can V.F. Corporation Face North and Land More Than Timber?
Insiders are buying, the CEO’s betting big, and the stitches are finally tightening at V.F. Corp. With a turnaround in motion and brands like Vans and Timberland in the mix, could this stock step back into fashion?
Penn Entertainment: A Double-Down That’s Finally Paying Off?
Penn Entertainment ($PENN) is showing signs of life — insiders are doubling down, revenues are climbing, and digital bets are growing fast. With shares rebounding, is it time to follow the high-rollers or step back from the table? 🎰📈
Viatris: The CEO Just Bought Shares… Should You Pop a Pill or Press "Buy"?
When a CEO personally buys over half a million dollars of stock, it’s time to pay attention. Viatris (VTRS) may be undervalued, with insider confidence, institutional backing, and a promising drug pipeline. But big losses and high debt mean it’s not risk-free. Is now the time to nibble?
Repay Holdings: Time to Reward the Patient Holder?
Insider buying is heating up at Repay Holdings. With over 200 institutions on board and a bargain-bin valuation, this fintech underdog might be getting ready to repay patient investors—with upside.
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?
🧴 International Flavors & Fragrances Stinks... No Longer?
IFF just reported a billion-dollar loss and still sports high debt, but insiders are loading up and institutional giants aren't flinching. It may still stink… or maybe it’s just getting interesting.